{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:23:05Z","timestamp":1756570985083},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.urology.2019.01.025","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T07:05:55Z","timestamp":1549350355000},"page":"116-120","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans"],"prefix":"10.1016","volume":"126","author":[{"given":"Alexander","family":"Christie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro L.","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2019.01.025_bib0001","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/j.1743-6109.2012.02976.x","article-title":"The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: erectile dysfunction among English-speakers","volume":"9","author":"Shaeer","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2019.01.025_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jacc.2011.07.051","article-title":"Cardiac uses of phosphodiesterase-5 inhibitors","volume":"59","author":"Schwartz","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.urology.2019.01.025_bib0003","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest Evidence on the use of Phosphodiesterase Type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.01.025_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2490-2-4","article-title":"Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital","volume":"2","author":"Sairam","year":"2002","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2019.01.025_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urology.2019.01.025_bib0006","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1755-148X.2010.00819.x","article-title":"Melanoma and viagra: an unexpected connection","volume":"24","author":"Mitra","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.urology.2019.01.025_bib0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.urology.2019.01.025_bib0008","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study","volume":"174","author":"Li","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2019.01.025_bib0009","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.eururo.2016.04.035","article-title":"Phosphodiesterase Type 5 inhibitors and the risk of melanoma skin cancer","volume":"70","author":"Lian","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2019.01.025_bib0010","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2015.6604","article-title":"Use of Phosphodiesterase Type 5 inhibitors for erectile dysfunction and risk of malignant melanoma","volume":"313","author":"Loeb","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2019.01.025_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002037","article-title":"Phosphodiesterase Type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK Clinical Practice Research Datalink","volume":"13","author":"Matthews","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.urology.2019.01.025_bib0012","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bjc.2016.248","article-title":"Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma","volume":"115","author":"Pottegard","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2019.01.025_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djx086","article-title":"Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma","volume":"109","author":"Loeb","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2019.01.025_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaad.2017.04.1129","article-title":"Phosphodiesterase Type 5 inhibitors and risk of melanoma: a meta-analysis","volume":"77","author":"Tang","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.urology.2019.01.025_bib0016","doi-asserted-by":"crossref","first-page":"46461","DOI":"10.18632\/oncotarget.17518","article-title":"Relation of Phosphodiesterase Type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.urology.2019.01.025_bib0017","unstructured":"R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/)"},{"key":"10.1016\/j.urology.2019.01.025_bib0018","unstructured":"Aragon T.J.: Epitools: Epidemiology Tools. R package. Version 0.5-10. 2017"},{"key":"10.1016\/j.urology.2019.01.025_bib0019","first-page":"818","article-title":"Erectile dysfunction medication use in veterans eligible for medicare part D","volume":"22","author":"Spencer","year":"2016","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519301311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429519301311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T12:47:30Z","timestamp":1606394850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429519301311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":18,"alternative-id":["S0090429519301311"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2019.01.025","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2019.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}